249 related articles for article (PubMed ID: 25042691)
1. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders.
Burrage LC; Jain M; Gandolfo L; Lee BH; ; Nagamani SC
Mol Genet Metab; 2014; 113(1-2):131-5. PubMed ID: 25042691
[TBL] [Abstract][Full Text] [Related]
2. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
Berry SA; Lichter-Konecki U; Diaz GA; McCandless SE; Rhead W; Smith W; Lemons C; Nagamani SC; Coakley DF; Mokhtarani M; Scharschmidt BF; Lee B
Mol Genet Metab; 2014 May; 112(1):17-24. PubMed ID: 24630270
[TBL] [Abstract][Full Text] [Related]
3. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Smith W; Diaz GA; Lichter-Konecki U; Berry SA; Harding CO; McCandless SE; LeMons C; Mauney J; Dickinson K; Coakley DF; Moors T; Mokhtarani M; Scharschmidt BF; Lee B
J Pediatr; 2013 Jun; 162(6):1228-34, 1234.e1. PubMed ID: 23324524
[TBL] [Abstract][Full Text] [Related]
4. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.
Lichter-Konecki U; Diaz GA; Merritt JL; Feigenbaum A; Jomphe C; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt B; Rhead W
Mol Genet Metab; 2011 Aug; 103(4):323-9. PubMed ID: 21612962
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Lee B; Rhead W; Diaz GA; Scharschmidt BF; Mian A; Shchelochkov O; Marier JF; Beliveau M; Mauney J; Dickinson K; Martinez A; Gargosky S; Mokhtarani M; Berry SA
Mol Genet Metab; 2010 Jul; 100(3):221-8. PubMed ID: 20382058
[TBL] [Abstract][Full Text] [Related]
6. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate.
Diaz GA; Krivitzky LS; Mokhtarani M; Rhead W; Bartley J; Feigenbaum A; Longo N; Berquist W; Berry SA; Gallagher R; Lichter-Konecki U; Bartholomew D; Harding CO; Cederbaum S; McCandless SE; Smith W; Vockley G; Bart SA; Korson MS; Kronn D; Zori R; Merritt JL; C S Nagamani S; Mauney J; Lemons C; Dickinson K; Moors TL; Coakley DF; Scharschmidt BF; Lee B
Hepatology; 2013 Jun; 57(6):2171-9. PubMed ID: 22961727
[TBL] [Abstract][Full Text] [Related]
7. Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.
Nagamani SC; Diaz GA; Rhead W; Berry SA; Le Mons C; Lichter-Konecki U; Bartley J; Feigenbaum A; Schulze A; Longo N; Berquist W; Gallagher R; Bartholomew D; Harding CO; Korson MS; McCandless SE; Smith W; Vockley J; Kronn D; Zori R; Cederbaum S; Merritt JL; Wong D; Coakley DF; Scharschmidt BF; Dickinson K; Marino M; Lee BH; Mokhtarani M
Mol Genet Metab; 2015; 116(1-2):29-34. PubMed ID: 26296711
[TBL] [Abstract][Full Text] [Related]
8. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients.
Scaglia F; Carter S; O'Brien WE; Lee B
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S79-85. PubMed ID: 15050979
[TBL] [Abstract][Full Text] [Related]
9. Phenylbutyrate therapy for maple syrup urine disease.
Brunetti-Pierri N; Lanpher B; Erez A; Ananieva EA; Islam M; Marini JC; Sun Q; Yu C; Hegde M; Li J; Wynn RM; Chuang DT; Hutson S; Lee B
Hum Mol Genet; 2011 Feb; 20(4):631-40. PubMed ID: 21098507
[TBL] [Abstract][Full Text] [Related]
10. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders.
Longo N; Diaz GA; Lichter-Konecki U; Schulze A; Inbar-Feigenberg M; Conway RL; Bannick AA; McCandless SE; Zori R; Hainline B; Ah Mew N; Canavan C; Vescio T; Kok T; Porter MH; Berry SA
Mol Genet Metab; 2021 Jan; 132(1):19-26. PubMed ID: 33388234
[TBL] [Abstract][Full Text] [Related]
11. Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment.
Molema F; Gleich F; Burgard P; van der Ploeg AT; Summar ML; Chapman KA; Lund AM; Rizopoulos D; Kölker S; Williams M;
Mol Genet Metab; 2019 Apr; 126(4):397-405. PubMed ID: 30827756
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial to examine the impact of food on pharmacokinetics of 4-phenylbutyrate and change in amino acid availability after a single oral administration of sodium 4-phenylbutyrarte in healthy volunteers.
Osaka S; Nakano S; Mizuno T; Hiraoka Y; Minowa K; Hirai S; Mizutani A; Sabu Y; Miura Y; Shimizu T; Kusuhara H; Suzuki M; Hayashi H
Mol Genet Metab; 2021 Apr; 132(4):220-226. PubMed ID: 33648834
[TBL] [Abstract][Full Text] [Related]
13. Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients.
Marini JC; Lanpher BC; Scaglia F; O'Brien WE; Sun Q; Garlick PJ; Jahoor F; Lee B
Am J Clin Nutr; 2011 Jun; 93(6):1248-54. PubMed ID: 21490144
[TBL] [Abstract][Full Text] [Related]
14. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Mokhtarani M; Diaz GA; Rhead W; Berry SA; Lichter-Konecki U; Feigenbaum A; Schulze A; Longo N; Bartley J; Berquist W; Gallagher R; Smith W; McCandless SE; Harding C; Rockey DC; Vierling JM; Mantry P; Ghabril M; Brown RS; Dickinson K; Moors T; Norris C; Coakley D; Milikien DA; Nagamani SC; Lemons C; Lee B; Scharschmidt BF
Mol Genet Metab; 2013 Dec; 110(4):446-53. PubMed ID: 24144944
[TBL] [Abstract][Full Text] [Related]
15. Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders.
Cederbaum SD; Edwards J; Kellmeyer T; Peters Y; Steiner RD
Mol Genet Metab; 2023 Apr; 138(4):107558. PubMed ID: 37004302
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of dietary treatment and amino acid supplementation in organic acidurias and urea-cycle disorders: On the basis of information from a European multicenter registry.
Molema F; Gleich F; Burgard P; van der Ploeg AT; Summar ML; Chapman KA; Barić I; Lund AM; Kölker S; Williams M;
J Inherit Metab Dis; 2019 Nov; 42(6):1162-1175. PubMed ID: 30734935
[TBL] [Abstract][Full Text] [Related]
17. Monitoring the treatment of urea cycle disorders using phenylbutyrate metabolite analyses: Still many lessons to learn.
Glinton KE; Minard CG; Liu N; Sun Q; Elsea SH; Burrage LC; Nagamani SCS
Mol Genet Metab; 2023 Nov; 140(3):107699. PubMed ID: 37717413
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders.
Monteleone JP; Mokhtarani M; Diaz GA; Rhead W; Lichter-Konecki U; Berry SA; Lemons C; Dickinson K; Coakley D; Lee B; Scharschmidt BF
J Clin Pharmacol; 2013 Jul; 53(7):699-710. PubMed ID: 23775211
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients.
Diaz GA; Schulze A; Longo N; Rhead W; Feigenbaum A; Wong D; Merritt JL; Berquist W; Gallagher RC; Bartholomew D; McCandless SE; Smith WE; Harding CO; Zori R; Lichter-Konecki U; Vockley J; Canavan C; Vescio T; Holt RJ; Berry SA
Mol Genet Metab; 2019 Aug; 127(4):336-345. PubMed ID: 31326288
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
McGuire BM; Zupanets IA; Lowe ME; Xiao X; Syplyviy VA; Monteleone J; Gargosky S; Dickinson K; Martinez A; Mokhtarani M; Scharschmidt BF
Hepatology; 2010 Jun; 51(6):2077-85. PubMed ID: 20512995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
